KR20240006519A - 항-siglec 조성물 및 이의 용도 - Google Patents

항-siglec 조성물 및 이의 용도 Download PDF

Info

Publication number
KR20240006519A
KR20240006519A KR1020237036789A KR20237036789A KR20240006519A KR 20240006519 A KR20240006519 A KR 20240006519A KR 1020237036789 A KR1020237036789 A KR 1020237036789A KR 20237036789 A KR20237036789 A KR 20237036789A KR 20240006519 A KR20240006519 A KR 20240006519A
Authority
KR
South Korea
Prior art keywords
ser
cancer
siglec
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237036789A
Other languages
English (en)
Korean (ko)
Inventor
양 리우
판 쩡
마틴 데벤포트
밍위에 리우
Original Assignee
온코씨4, 아이앤씨.
유니버시티 오브 매릴랜드, 발티모어
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코씨4, 아이앤씨., 유니버시티 오브 매릴랜드, 발티모어 filed Critical 온코씨4, 아이앤씨.
Publication of KR20240006519A publication Critical patent/KR20240006519A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237036789A 2021-04-30 2022-04-29 항-siglec 조성물 및 이의 용도 Pending KR20240006519A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182271P 2021-04-30 2021-04-30
US63/182,271 2021-04-30
PCT/US2022/027006 WO2022232558A1 (en) 2021-04-30 2022-04-29 Anti-siglec compositions and uses thereof

Publications (1)

Publication Number Publication Date
KR20240006519A true KR20240006519A (ko) 2024-01-15

Family

ID=83848703

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237036789A Pending KR20240006519A (ko) 2021-04-30 2022-04-29 항-siglec 조성물 및 이의 용도

Country Status (11)

Country Link
US (1) US20240218067A1 (https=)
EP (1) EP4329806A4 (https=)
JP (1) JP2024515879A (https=)
KR (1) KR20240006519A (https=)
CN (1) CN117355331A (https=)
AU (1) AU2022267362A1 (https=)
CA (1) CA3216324A1 (https=)
IL (1) IL308137A (https=)
MX (1) MX2023012759A (https=)
TW (1) TW202305005A (https=)
WO (1) WO2022232558A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117643575B (zh) * 2023-11-03 2026-04-24 中山大学 一种纳米材料及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120171114A1 (en) * 2008-04-11 2012-07-05 Haeuw Jean-Francois Anti-cd151 antibodies and their use in the treatment of cancer
US8163281B2 (en) * 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
TW201612518A (en) * 2014-01-17 2016-04-01 Sanofi Sa Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody
CA3004972A1 (en) * 2015-11-17 2017-05-26 Innate Pharma Siglec-10 antibodies
KR20210143868A (ko) * 2019-03-26 2021-11-29 포티 세븐, 인코포레이티드 암 치료용 다중특이성 제제

Also Published As

Publication number Publication date
EP4329806A1 (en) 2024-03-06
EP4329806A4 (en) 2025-09-17
TW202305005A (zh) 2023-02-01
CN117355331A (zh) 2024-01-05
IL308137A (en) 2023-12-01
MX2023012759A (es) 2023-11-13
AU2022267362A1 (en) 2023-11-09
CA3216324A1 (en) 2022-11-03
WO2022232558A1 (en) 2022-11-03
US20240218067A1 (en) 2024-07-04
AU2022267362A9 (en) 2023-11-16
JP2024515879A (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
AU2023203169B2 (en) Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
TWI870335B (zh) 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
US20250043003A1 (en) Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
KR20190130137A (ko) 종양 특이적 세포 고갈을 위한 fc-최적화된 항-cd25
JP2022512642A (ja) がんを治療するための抗ＭｅｒＴＫ抗体
CA3203257A1 (en) Anti-b7-h3 antibody and uses thereof
WO2020058762A1 (en) Antibodies specific to ctla-4 and uses thereof
US20240218067A1 (en) Anti-siglec compositions and uses thereof
EA049996B1 (ru) Антитело к siglec-10 (варианты)
CN114630679A (zh) 抗garp抗体和免疫调节剂的组合
EP4494655A1 (en) Combination of multi-specific molecule and immune checkpoint inhibitor
HK40115416A (en) Combination of multi-specific molecule and immune checkpoint inhibitor
TW202241511A (zh) 新穎抗體組合及其用途
HK40016585A (en) Fc-optimized anti-cd25 for tumor specific cell depletion
HK1259883B (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250428

Comment text: Request for Examination of Application